Functional evidence for the ability of angiotensin AT1 receptor antagonists to cross the blood-brain barrier in rats

https://doi.org/10.1016/0014-2999(96)00270-1Get rights and content

Abstract

The angiotensin AT1 receptor antagonists, losartan (2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2′(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole potassium salt), EXP3174 (2-n-butyl-4-chloro-1-[(2′(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid), GR117289 (1-[[3-bromo-2-[2-(1H-tetrazol-5-yl)phenyl]-5-benzofuranyl]methyl]-2-butyl-4-chloro-1H-imidazole-5-carboxylic acid) and LR-B/081 (methyl-2-[[4-butyl-2-methyl-6-oxo-5-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1(6H)-pyrimidinyl]methyl]-3-thiophenecarboxylate), given by intraperitoneal (i.p.) injection 15 min before intracerebroventricular administration of angiotensin II, inhibited drinking with the following order of potency: EXP3174 > GR117289 > losartan > LR-B/081. When 20 μmol/kg of each antagonist was i.p. injected 15 min, 4, 12 or 24 h before angiotensin II, EXP3174 and GR117289 inhibited water intake at each observation time, losartan at 4, 12 and 24 h, LR-B/081 only at 4 and 12 h. After per os administration of the same dose 4 or 12 h before angiotensin II, losartan reduced drinking at 4, but not at 12 h; LR-B/081 did not inhibit drinking either at 4 or 12 h. The present results suggest that EXP3174 and GR117289 cross the barrier readily. The effect of i.p. losartan on central angiotensin mechanisms is not prompt, suggesting that it may require conversion to EXP3174. LR-B/081 apparently crosses the barrier less readily than the other antagonists following both i.p. and per os administration.

References (42)

  • M.J. Beresford et al.

    Intracerebroventricular angiotensin II-induced thirst and sodium appetite in rats are blocked by the AT1 receptor antagonist, losartan (DuP 753), but not by the AT2 antagonist, CGP 42112B

    Exp. Physiol.

    (1992)
  • D.J. Carini et al.

    Angiotensin II receptor blocking Imidazoles

    (1988)
  • R. Cirillo et al.

    Pharmacology of LR-B/081, a new highly potent, selective and orally active, nonpeptide angiotensin II AT1 receptor antagonist

    Br. J. Pharmacol.

    (1995)
  • R.P. Dennes et al.

    Differential effects of the AT1 receptor antagonists GR117289 and GR 138950 on AT1 receptor-mediated dipsogenic responses and in a brain ex vivo binding assay in the rat

    Br. J. Pharmacol.

    (1993)
  • A.E. Doyle et al.

    Hypertension and the Angiotensin System: Therapeutic Approaches

    (1984)
  • A.N. Epstein

    Prospectus: thirst and salt appetite

  • J.T. Fitzsimons

    The Physiology of Thirst and Sodium Appetite

  • J.T. Fitzsimons

    Endogenous angiotensin and sodium appetite

  • M.J. Fregley et al.

    Effect of a non peptide angiotensin II receptor antagonist, Dup753, on angiotensin-related water intake in rats

    Brain Res. Bull.

    (1991)
  • T.W. Gardner et al.

    Impaired drinking responses of rats with lesions of the nucleus medianus: circadian dependence

    Am. J. Physiol.

    (1985)
  • A. Hilditch et al.

    Cardiovascular effects of GR117289, a novel angiotensin AT1 receptor antagonist

    Br. J. Pharmacol.

    (1994)
  • Cited by (55)

    • Preliminary study of ovariectomy and chronic losartan-induced alterations in brain AT<inf>1</inf> receptors

      2021, Brain Research
      Citation Excerpt :

      Previously, we showed that the ARB, losartan prevents anxiety-like behavior and cognitive impairments induced by ovariectomy in a normotensive Long-Evans rats (Campos et al., 2019). To explore this relationship, we assessed changes in brain AT1 receptor binding in 5 brain regions as a function of ovariectomy and treatment with the ARB losartan, which has been shown to cross the blood–brain-barrier to inhibit AT1R binding and activation (Song et al., 1991; Li et al., 1993; Polidori et al., 1996) when administered peripherally. There was a significant difference in brain AT1R binding between brain regions, but no significant difference between males and females except for a trend toward increased AT1R expression in the intact male amygdala compared to the sham-vehicle female.

    • Angiotensinergic neurotransmission in the paraventricular nucleus of the hypothalamus modulates the pressor response to acute restraint stress in rats

      2014, Neuroscience
      Citation Excerpt :

      The dose of losartan presently used was chosen considering previous reports in the literature (Kauffman et al., 1991; Levine et al., 1996; Wang et al., 1997), including a pharmacokinetic study on losartan (Moon et al., 1998). Concerning action on the CNS, there is evidence in the literature indicating that AT1-antagonists cross the blood–brain barrier and act in the CNS (Li et al., 1993; Polidori et al., 1996; Nishimura et al., 2000), and that losartan central effects would last longer than restraining session duration (>60 min). The antagonism produced by a 3-mg/kg i.v. dose of losartan on the local neuronal activation resulting from AngII microinjection into the PVN has been reported to last for 75 min (Li et al., 1993), whereas that observed after the i.p. administration of a 10-mg/kg dose of losartan on rat water intake remained for 24 h (Polidori et al., 1996).

    • Angiotensin-(1-7)/Mas axis integrity is required for the expression of object recognition memory

      2012, Neurobiology of Learning and Memory
      Citation Excerpt :

      Losartan (Sigma–Aldrich) 10 mg/kg was administered by intraperitoneal (i.p.) injection, 18 h and 1 h prior training (Raghavendra, Chopra, & Kulkarni, 2001). It is well accepted that this dose of losartan crosses the brain blood barrier and functionally blocks their targets in the brain (Polidori, Ciccocioppo, Pompei, Cirillo, & Massi, 1996; Tota et al., 2009; Wang, Tan, & Leenen, 2003). PD123319 (Sigma–Aldrich) 1 mg/kg was administered by subcutaneous (s.c.) injection, 12 h and 1 h before training session (Macova, Pavel, & Saavedra, 2009).

    View all citing articles on Scopus
    1

    Present address: Menarini Ricerche Sud, Via Tito Speri 10, 00040 Pomezia, Rome, Italy.

    View full text